Harpoon Therapeutics, Inc. Common Stock
HARP
HARP was delisted on the 8th of March, 2024.
63 hedge funds and large institutions have $37.6M invested in Harpoon Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 23 reducing their positions, and 26 closing their positions.
200% more call options, than puts
Call options by funds: $57K | Put options by funds: $19K
20% less funds holding
Funds holding: 79 → 63 (-16)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
48% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 23
58% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 26
71% less capital invested
Capital invested by funds: $128M → $37.6M (-$90.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.46M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$335K |
| 3 |
Renaissance Technologies
New York
|
+$275K |
| 4 |
E
Ergoteles
New York
|
+$238K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$186K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$2.77M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.47M |
| 3 |
BlackRock
New York
|
-$2.25M |
| 4 |
State Street
Boston,
Massachusetts
|
-$915K |
| 5 |
Franklin Resources
San Mateo,
California
|
-$877K |
HARP Hedge Fund Activity: Q2 2022 in Review
63 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q2 2022, worth a combined $37.6M — down 71% from $128M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of HARP and 11 opened new positions — a net loss of 15 holders — while 23 trimmed existing stakes and 12 added.
The largest buyer was Millennium Management, adding an estimated $1.46M. The largest seller was International Biotechnology Trust, exiting entirely with an estimated $2.77M sold.
- 63 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q2 2022, down from 79 in Q1 2022.
- Funds reported $37.6M of Harpoon Therapeutics, Inc. Common Stock stock for Q2 2022, down 71% quarter-over-quarter.
- 11 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q2 2022 and 26 closed out, a net change of -15 holders.
- The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q2 2022 was Millennium Management, an estimated $1.46M added.
- The largest Harpoon Therapeutics, Inc. Common Stock seller in Q2 2022 was International Biotechnology Trust, an estimated $2.77M sold.
Based on aggregated 13F filings for Q2 2022.